Showing results (31-40 of 315) with videos related to
Sort By:
Pageof 32
Current Pharmaceutical Design|March 7, 2006
Controversies of androgen ablation therapy for metastatic prostate cancerShandra S Wilson, E David CrawfordCurrent Oncology Reports|April 7, 2004
Artificial neural networks for predictive modeling in prostate cancerEduard J Gamito, E David CrawfordOncology (Williston Park, N.Y.)|January 17, 2015
ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injuryE David Crawford, Judd W MoulOncology (Williston Park, N.Y.)|July 25, 2009
The role of LHRH antagonists in the treatment of prostate cancerE David Crawford, Amy H HouOncology (Williston Park, N.Y.)|February 5, 2010
Metastatic cancer in solid tumors and clinical outcome: skeletal-related eventsKyle O Rove, E David CrawfordCancer Journal (Sudbury, Mass.)|October 9, 2007
The current use and future trends of focal surgical therapy in the management of localized prostate cancerAl B Barqawi, E David CrawfordUrologic Oncology|November 15, 2011
New and emerging agents for the treatment of castration-resistant prostate cancerCelestia S Higano, E David CrawfordAsian Journal of Andrology|October 23, 2014
To screen or nor to screen: the prostate cancer dilemmaNelson N Stone, E David CrawfordCurrent Opinion in Urology|March 16, 2013
Androgen annihilation as a new therapeutic paradigm in advanced prostate cancerKyle O Rove, E David CrawfordBest Practice & Research. Clinical Endocrinology & Metabolism|May 13, 2008
The benefits of early androgen blockadePaul D Maroni, E David CrawfordPageof 32